OraSure Technologies Receives $8.6 Million BARDA Contract to Develop 2nd Generation Ebola Test

September 28, 2022

https://www.globenewswire.com/news-release/2022/09/28/2524158/11732/en/OraSure-Technologies-Receives-8-6-Million-BARDA-Contract-to-Develop-2nd-Generation-Ebola-Test.html

BETHLEHEM, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ:OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Biomedical Advanced Research and Development Authority (BARDA) has issued the Company an $8.6 million contract to develop a 2nd generation Ebola test on the OraQuick® testing platform. The goal is for the 2nd generation test to have improved sensitivity, increased shelf life, new chemistry and more automation when compared to the de novo U.S. Food and Drug Administration (FDA) authorized test. OraSure’s OraQuick® Ebola Rapid Antigen test is the only test today with a de novo authorization from the FDA and has been used extensively for Ebola cadaver testing in Africa with results available in 30 minutes.

Read more at globenewswire.com

Related news for (OSUR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.